HD-OPM Archive
Topics › Risk assessment & lab tests

Thickened Achilles tendon predicts MACE after stenting: 28.4% vs 17.9%

Louis Nervegna · Mar 13, 2026 · ♥ 6 reactions · 3 comments · original Facebook post
Risk assessment & lab testsLDL, ApoB & lipid panel
AI summary & key facts

Louis shares a 2026 Circulation Journal study showing Achilles tendon thickening (at least 8 mm men, 7.5 mm women) predicts major adverse cardiovascular events within three years after PCI, likely reflecting cumulative LDL exposure.

A thickened Achilles tendon (≥8 mm in men, ≥7.5 mm in women) is a significant prognostic marker for cardiovascular risk.

A 2026 study showed these patients face a much higher risk of major adverse cardiovascular events (MACE) within three years after a stent procedure compared to those without thickening:

Paper · Circ J · 2026Prognostic Impact of Achilles Tendon Thickening After Percutaneous Coronary Intervention Compared Between Acute and Chronic Coronary Syndromes.Conclusion: ATT may be a simple, non-invasive marker for risk stratification after PCI, particularly in ACS patients.pubmed.ncbi.nlm.nih.gov

Findings on Achilles Tendon Thickening and Heart Health

While this study didn't establish direct causation, it supports using the physical assessment of the Achilles tendon for secondary prevention and risk stratification in cardiology.

Why the Achilles Tendon?

The connection lies in how our bodies handle LDL over decades.

Quoted:

“A total of 1,362 patients were analyzed: 387 (28.4%) ACS [acute coronary syndrome] and 975 (71.6%) CCS [chronic coronary syndrome] patients. Overall, ATT [achilles tendon thickening] was observed in 228 patients (16.7%). The prevalence of ATT was significantly higher in ACS than CCS patients (24.3% vs. 13.7%, P<0.001). Kaplan-Meier curve analysis demonstrated that the incidence of 3-year MACE after PCI was 28.4% in the ATT group and 17.9% in the no ATT group (hazard ratio [HR] 1.99, 95% confidence interval [CI] 1.38-2.87, P<0.001) (Figure). In ACS patients, 3-year MACE occurred more frequently in the ATT group (HR 4.74, 95% CI 2.02-11.1, P=0.001). A similar trend was observed in the CCS patients, but did not reach statistical significance HR 1.63, 95% CI 1.00-2.59, P=0.066).”

#achillestendonHD

Research cited

#cholesterol#cardiovascular#riskfactors#hearthealth#bloodtests#stents#stroke#carotid
← newer: 2026 ACC/AHA lipid guideline keeps LDL targets and adds Lp(aolder: Statins do not cause dementia or cognitive decline and may b →